Research on psilocybin and multiple sclerosis

Introduction: the revival of psychedelic research

In recent years psychedelic research has been experiencing a remarkable renaissance. Psilocybin, the primary psychoactive component of certain mushroom species (such as Psilocybe cubensis and Psilocybe semilanceata), has attracted the interest of the neuroscience community because of its unique neurobiological effects.

In the context of multiple sclerosis, a chronic inflammatory, demyelinating disease of the central nervous system, the neuroplasticity-promoting and anti-inflammatory properties of psilocybin offer promising therapeutic perspectives.

Pharmacology and mechanisms of action

Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is a prodrug that is rapidly dephosphorylated to psilocin (4-hydroxy-N,N-dimethyltryptamine) after oral intake. Psilocin is the actual psychoactive metabolite and acts primarily as an agonist at serotonin 5-HT2A receptors.

Key receptor interactions

• 🔬
  5-HT2A receptor agonism - main mechanism of the psychedelic effect, leads to increased cortical activity and neuroplasticity
• 🔬
  5-HT2C and 5-HT1A - additional serotonin receptor interactions modulate mood and anxiety
• 🔬
  Glutamate release - increased glutamatergic transmission in the prefrontal cortex promotes synaptic plasticity

Neuroplasticity and BDNF

One of the most fascinating aspects of psilocybin is its ability to promote neuroplasticity. Studies have shown that a single dose of psilocybin can lead to an increase in dendritic density and synaptic connections, an effect that persists beyond the acute psychoactive effect.

Brain-derived neurotrophic factor (BDNF) plays a central role in this process. Preclinical studies show that psilocybin significantly increases BDNF expression in the hippocampus and prefrontal cortex. In MS BDNF is of particular relevance, as it could support remyelination and mitigate neuronal damage.

Anti-inflammatory properties

Neuroinflammation is a core feature of MS pathophysiology. Activated microglia and infiltrating T cells release proinflammatory cytokines that contribute to demyelination and axonal damage.

In preclinical models psilocybin shows promising anti-inflammatory effects:

• Reduction of TNF-α, IL-6 and IL-1β in microglia
• Inhibition of NF-κB signaling pathways
• Promotion of an anti-inflammatory microglial phenotype (M2)
• Reduction of oxidative stress through increased antioxidant enzyme activity

Mental comorbidity in MS

MS patients have a significantly increased risk of psychiatric comorbidities. The lifetime prevalence of depression in MS is about 50%, compared with 10-15% in the general population. Anxiety disorders affect up to 36% of patients.

Psilocybin-assisted psychotherapy has shown remarkable success in treatment-resistant depression in clinical trials. The COMP360 studies by Compass Pathways showed remission rates of over 30% after a single treatment.

Microdosing: an alternative approach

Microdosing refers to the regular intake of sub-psychoactive doses of psilocybin (typically 0.1-0.3 g of dried mushrooms or 10-20% of a full dose). This regimen aims to achieve neurobiological benefits without the acute psychedelic effects.

Anecdotal reports and first scientific investigations point to possible benefits: improved mood, increased creativity, reduced anxiety and possibly improved cognitive function. However, the evidence base is still limited and controlled studies are needed.

Safety profile and contraindications

Psilocybin has a favorable safety profile compared with many other psychoactive substances. It does not cause physical dependence and the lethal dose is extremely high.

Important contraindications include:

• ⚠️
  Psychotic disorders - personal or family history of schizophrenia or bipolar disorder (manic episodes)
• ⚠️
  Cardiovascular disease - psilocybin can temporarily raise blood pressure and heart rate
• ⚠️
  Pregnancy and breastfeeding - insufficient safety data

Conclusion and outlook

Preclinical and early clinical research suggests that psilocybin could offer multiple therapeutic starting points in MS: promotion of neuroplasticity, reduction of neuroinflammation and improvement of mental health.

Although the direct clinical evidence for psilocybin in MS is still limited, the promising results from related fields of research justify further investigation. The development of specific clinical trials for MS patients should be a priority of the psychedelic research community.

Beyond psilocybin: other promising substances

Besides psilocybin, other psychedelic and psychoactive substances are being investigated for their neuroregenerative potential in MS and other neurodegenerative diseases.

2-Bromo-LSD (BOL-148)

2-Bromo-LSD is a non-psychoactive derivative of LSD that may show the 5-HT2A receptor-mediated neuroplastic effects without the psychedelic experience. Early studies show promising results in cluster headache and could be extended to other neurological applications.

Ibogaine and tabernanthalog

Ibogaine, an alkaloid from the African plant Tabernanthe iboga, has shown remarkable neuroprotective properties. Tabernanthalog is a synthetic, non-toxic analog that could offer the neuroplastic effects without the cardiotoxic risks.

DMT and ayahuasca

Dimethyltryptamine (DMT) activates the sigma-1 receptor, which is involved in the regulation of neuroinflammation and oxidative stress. Preclinical studies show that DMT can promote neurogenesis in the hippocampus and have anti-inflammatory effects.